Global Hemoglobinopathies Treatment Market 2019-2023

Some of the key findings from our hemoglobinopathies treatment market forecast report are summarized below

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global hemoglobinopathies treatment industry overview

The unavailability of an effective treatment without any or few side effects is encouraging pharmaceutical companies to develop promising therapeutics for hemoglobinopathies treatment. For instance, trial and subject recruiting are ongoing for Phase III of a randomized, parallel group, double-blind, multicenter study by AstraZeneca. This study is expected to be completed by November 2020 and is aimed at evaluating the efficacy of ticagrelor versus placebo in reducing vaso-occlusive crises rate in SCD pediatric patients. The development of luspatercept (ACE-536) by CELGENE for the treatment of transfusion-dependent β-thalassemia is also in Phase III stage. Similarly, several other late-stage pipeline molecules are expected to be available during the next five years.

The current lack of approved therapies will further boost the demand for hemoglobinopathies treatment market growth. The global hemoglobinopathies treatment is expected to grow at a CAGR of almost 11% during the forecast period.

Top hemoglobinopathies treatment companies covered in this market research report

The global hemoglobinopathies treatment market is moderately concentrated and the market being in a growth phase, the competition among companies is intense. To help clients improve their revenue shares in the market, this research report provides an analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this hemoglobinopathies treatment market analysis report suggests strategies companies can follow and recommends key areas they should focus on, to make the most of upcoming growth opportunities.

The report offers a detailed analysis of several leading companies, including:

• ApoPharma
• Bristol-Myers Squibb
• Emmaus Medical
• Medunik USA
• Novartis

Hemoglobinopathies treatment market segmentation based on the type

• Sickle cell disease
• Thalassemia

The sickle cell disease (SCD) segment will account for the highest share in the hemoglobinopathies treatment market because of the recent drug approvals for the treatment of SCD. Additionally, the report also provides an accurate prediction of the contribution of the various types of segments to the growth of the hemoglobinopathies treatment market size.

Hemoglobinopathies treatment market segmentation based on geographic region

• Americas
• APAC
• EMEA

A complete study of the growth opportunities in the hemoglobinopathies treatment market indicates, the Americas will account for the highest growth of the hemoglobinopathies treatment market throughout the forecast period. Increasing awareness of thalassemia and the growing prevalence of SCD are some of the factors driving hemoglobinopathies treatment market growth in this region.

Key highlights of the global hemoglobinopathies treatment market for the forecast years 2019-2023:

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the hemoglobinopathies treatment market during the next five years
• Precise estimation of the global hemoglobinopathies treatment market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the hemoglobinopathies treatment industry across the Americas, APAC, and EMEA
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details on factors that will challenge the growth of hemoglobinopathies treatment companies 

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch